STOCK TITAN

[144] Apellis Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Apellis Pharmaceuticals insider Cedric Francois has filed a Form 144 to potentially sell 8,182 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $161,945.51 based on the figures in the notice. The stock was acquired on 01/16/2026 through restricted stock vesting from the issuer as compensation.

The notice also reports that during the past three months, Francois sold 10,186 shares of common stock on 01/13/2026 for gross proceeds of $225,998.82. By signing the notice, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.

Positive

  • None.

Negative

  • None.

Insights

Routine Form 144 filing discloses planned sale of recently vested shares.

This filing shows Cedric Francois has notified of an intent to sell up to 8,182 shares of Apellis Pharmaceuticals common stock. The shares were acquired on 01/16/2026 via restricted stock vesting as compensation, and the planned sale is routed through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $161,945.51 based on the amounts listed.

The disclosure also lists a prior sale during the last three months: 10,186 common shares sold on 01/13/2026 for gross proceeds of $225,998.82. Form 144 is a notice requirement for affiliates and large holders and, by itself, does not guarantee that all noticed shares will be sold, but it signals potential selling activity tied to equity compensation.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Apellis Pharmace

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Latest SEC Filings

APLS Stock Data

2.65B
106.56M
13.68%
105.74%
16.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM